<p>The Cancer and Leukemia Group B (CALGB) 90401 trial compared docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer. A genome-wide association study using clinical outcomes and toxicities was conducted on the basis of data from CALGB patients who provided consent for pharmacogenomic studies and usable DNA</p>

A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind,    Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone    with or without Bevacizumab in Men with Metastatic    Castration-Resistant Prostate Cancer

A Genome-Wide Association Study of CALGB 90401: Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone with or without Bevacizumab in Men with Metastatic Castration-Resistant Prostate Cancer

Description

Applying For Access

Summary